Page last updated: 2024-12-05

1,4-cyclohexanediol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1,4-Cyclohexanediol: A Versatile Building Block

1,4-Cyclohexanediol is a cyclic diol, meaning it's a six-membered ring containing two hydroxyl (-OH) groups at positions 1 and 4. It is a white, crystalline solid with a melting point of 102-104 °C.

**Why is 1,4-cyclohexanediol important for research?**

1. **Versatile building block:** It serves as a valuable starting material for the synthesis of various organic compounds, including pharmaceuticals, polymers, and agrochemicals. Its two hydroxyl groups provide reactivity for a wide range of chemical transformations.
2. **Chirality and enantiomers:** The molecule exists in two enantiomeric forms (cis and trans) due to the different spatial arrangements of the hydroxyl groups. These different enantiomers can exhibit different biological activities, making them valuable for drug development.
3. **Polymers and materials:** 1,4-Cyclohexanediol can be incorporated into polymers, leading to materials with desired properties like flexibility, strength, and biodegradability.
4. **Pharmaceuticals:** It's used as an intermediate in the synthesis of various pharmaceutical compounds, such as anti-inflammatories, anti-cancer drugs, and antibiotics.
5. **Agrochemicals:** It's a crucial component in the synthesis of pesticides and herbicides that enhance crop yields and protect against pests and diseases.

**Research applications of 1,4-cyclohexanediol:**

* **Synthesis of chiral catalysts:** Its enantiomeric forms can be used to design chiral catalysts for enantioselective synthesis, leading to more efficient and environmentally friendly chemical processes.
* **Development of biodegradable polymers:** It's being explored as a building block for biodegradable polymers that could offer environmentally friendly alternatives to traditional plastics.
* **Design of novel drug candidates:** Its unique structure and functional groups make it a promising starting point for the development of novel drugs with improved efficacy and reduced side effects.

Overall, 1,4-cyclohexanediol is a versatile and valuable molecule with significant potential for research and development in various fields, ranging from materials science to pharmaceutical chemistry. Its unique structural features, combined with its reactivity, make it a cornerstone for the development of new and innovative technologies.

Cross-References

ID SourceID
PubMed CID11162
CHEMBL ID3948618
SCHEMBL ID275681
SCHEMBL ID102859
SCHEMBL ID28182
SCHEMBL ID787503
MeSH IDM0177982

Synonyms (77)

Synonym
nsc5730
556-48-9
nsc5651
1,4-cyclohexanediol ,
nsc-5730
quinitol
6995-79-5
trans-1,4-dihydroxycyclohexane
trans-1,4-cyclohexanediol
nsc-5651
1,4-cyclohexanediol, trans-
1,4-cyclohexanediol, cis-
cis-1,4-cyclohexanediol
cyclohexane-1,4-diol
1,4-cyclohexanediol, 99%
cis-1,4-dihydroxycyclohexane
1,4-dihydroxycyclohexane
C2319
931-71-5
C2320
AKOS006282972
AKOS006283462
hexahydrohydroquinone
cis-cyclohexane-1,4-diol
EN300-75448
A830732
nsc 5730
ai3-06464
einecs 213-240-8
einecs 209-126-2
nsc 5651
ai3-52305
FT-0606824
trans-cyclohexane-1,4-diol
AB02551
PB27420
AKOS015912876
1,4-cyclohexanediol, cis + trans
TD8009
SCHEMBL275681
SCHEMBL102859
SCHEMBL28182
1,4-cyclohexanediol,c&t
1,4-cyclohexanediol cis+trans
quinitol,c&t
1,4-cyclohexanediol, (z)-
J-700165
1,4-cyclohexandiol
cis-4-hydroxy-cyclohexanol
mfcd00075462
mfcd00063612
(trans)-cyclohexane-1,4-diol
(1r,4r)-cyclohexane-1,4-diol
SCHEMBL787503
Q-200861
Q-201852
STR08594
1,4-cyclohexanediol, (e)-
CHEMBL3948618
(1s,4s)-cyclohexane-1,4-diol
CS-W007850
CS-W005575
mfcd00001448
FT-0726556
71J ,
CS-0049754
SY040970
AS-50386
Q16912255
DTXSID20871178
DTXSID60883614
DTXSID60878843
P10063
rac-(1s,4s)-cyclohexane-1,4-diol
SY001809
SY099933
Z1178486717
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's3 (21.43)18.2507
2000's4 (28.57)29.6817
2010's5 (35.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.04 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index55.02 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]